Ovid Therapeutics (OVID) investor relations material

Executive summary

• OV329, a next-generation GABA-AT inhibitor, advanced with strong safety and tolerability at up to 7 mg, supporting expansion into infantile spasms and tuberous sclerosis complex seizures.

• OV4071, a first-in-class oral KCC2 direct activator, received regulatory clearance for Phase 1 trials, targeting psychoses, neurodegenerative conditions, and Parkinson's disease-related psychosis.

• $60M PIPE/private placement financing secured, with potential for an additional $53M–$53.9M from Series A warrant exercises, extending cash runway into 2029.

• New clinical programs launched for OV329 in rare pediatric epilepsies, with multiple clinical milestones and regulatory readouts expected through 2027.

• Cash, cash equivalents, and marketable securities totaled $90.4M as of December 31, 2025.

Financial highlights

• Cash, cash equivalents, and marketable securities were $90.4M as of December 31, 2025, up from $53.1M at year-end 2024.

• $60M PIPE/private placement financing announced, with additional potential proceeds from Series A warrants up to $53.9M.

• Revenue for Q4 2025 was $0.7M and $7.3M for FY 2025, including a one-time $7.0M payment.

• Research and development expenses were $6.6M for Q4 2025 and $25.6M for FY 2025, down year-over-year.

• Net income for Q4 2025 was $9.7M, driven by a $21.0M gain on long-term equity investment adjustment.

Outlook and guidance

• Multiple clinical milestones expected through 2026–2027, including proof-of-concept and pivotal studies for OV329 and OV4071.

• Phase II trials for OV329 in focal onset seizures and phase I for OV4071 to begin in Q2 2026.

• Proof-of-concept studies for OV329 in TSC seizures and IS planned for Q4 2026 and 2027.

• Additional preclinical and clinical data for KCC2 portfolio to be presented at an R&D day in April.

• Potential for accelerated registration paths and orphan status for key indications.